Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP481947.RAv6FYfZsegieUQPYWaETnWMOgpWbPVyznmzOodTwQ9j8130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP481947.RAv6FYfZsegieUQPYWaETnWMOgpWbPVyznmzOodTwQ9j8130_provenance.
• NP914665.RAZovdKimApYrvKKkUm6eengADc5n2a2Cw4ow6W1sirFE130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914665.RAZovdKimApYrvKKkUm6eengADc5n2a2Cw4ow6W1sirFE130_provenance.
• assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP413024.RAH_XbIKfQ_Kl2odIwY4vkURA_xSdHQukl-95_v0WfIbI130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP413024.RAH_XbIKfQ_Kl2odIwY4vkURA_xSdHQukl-95_v0WfIbI130_provenance.
• NP229124.RA6p34GYPKmG3KO4ubv_iaIR_1KqCtQ7FQp56w2Q0KwKE130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP229124.RA6p34GYPKmG3KO4ubv_iaIR_1KqCtQ7FQp56w2Q0KwKE130_provenance.
• NP732539.RA7ze3RmdpuA2-q__GFflDC6ZvTADS4LFphOGYPVNXq1Y130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732539.RA7ze3RmdpuA2-q__GFflDC6ZvTADS4LFphOGYPVNXq1Y130_provenance.
• NP678306.RAdvFXehvZyFRXyK4_1LJX970Ars-O00Fx0vurKBNdKgo130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP678306.RAdvFXehvZyFRXyK4_1LJX970Ars-O00Fx0vurKBNdKgo130_provenance.
• assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP933493.RAewGuwL1UTgH7B3IVej9dUXrC4kLX-zHJxUJUHAK555E130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933493.RAewGuwL1UTgH7B3IVej9dUXrC4kLX-zHJxUJUHAK555E130_provenance.
• NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933496.RATESfeMsY_VATkxw1pfCwTaAuajH94En-AFXwo_yqLS8130_provenance.
• NP462469.RAnecoZUDieG4snZ6jkACNuDSqhPKOvtos7n_JWmIZbfo130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP462469.RAnecoZUDieG4snZ6jkACNuDSqhPKOvtos7n_JWmIZbfo130_provenance.
• NP678421.RAm7qPI_pr8jw8UekDEqwwuvRVuA31XdmmfAo8JG8emr8130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP678421.RAm7qPI_pr8jw8UekDEqwwuvRVuA31XdmmfAo8JG8emr8130_provenance.
• NP462587.RA1765aAamzcznNIoarzS2iYPOXlbEK706KpvlzCbQnwE130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP462587.RA1765aAamzcznNIoarzS2iYPOXlbEK706KpvlzCbQnwE130_provenance.
• NP462599.RAzjyJh9qsaL-roQ2V-PN9vrUYGtE7MsOBGzOz-UlXCYQ130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP462599.RAzjyJh9qsaL-roQ2V-PN9vrUYGtE7MsOBGzOz-UlXCYQ130_provenance.
• NP678432.RA0LTHIEiQR7belHcUruhmxY6ZgrOl1BCVufwMPYBDHUA130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP678432.RA0LTHIEiQR7belHcUruhmxY6ZgrOl1BCVufwMPYBDHUA130_provenance.
• NP933494.RAP1ZAinQt1jFvE1wIPtl0fE5-YWcZmR8Gb5wwIym4RMk130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933494.RAP1ZAinQt1jFvE1wIPtl0fE5-YWcZmR8Gb5wwIym4RMk130_provenance.
• NP933495.RAIC4VwAv86T_qMv5dfErV8175Vh9EsAEmz3umQC-ZYro130_assertion description "[With regard to the mechanism of therapy using AAV8-IL24 in MLL/AF4-positive ALL, we demonstrated the antiangiogenicity and effects on the ER stress pathway and unreported pathways through inhibition of S100A6 and HOXA9, which is specific to MLL/AF4-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933495.RAIC4VwAv86T_qMv5dfErV8175Vh9EsAEmz3umQC-ZYro130_provenance.